

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
10/664,008	09/16/2003	Benedikt Sas	4532680/16900 (KEM 69)	3907
26386	7590 11/03/2006		EXAMINER	
DAVIS, BR	OWN, KOEHN, SHORS	WANG, SHENGJUN		
THE FINAN	CIAL CENTER			
666 WALNUT STREET SUITE 2500 DES MOINES, IA 50309-3993			ART UNIT	PAPER NUMBER
			1617	
			DATE MAILED: 11/03/2006	

Please find below and/or attached an Office communication concerning this application or proceeding.

	T	
	Application No.	Applicant(s)
	10/664,008	SAS ET AL.
Office Action Summary	Examiner	Art Unit
	Shengjun Wang	1617
The MAILING DATE of this communication ap Period for Reply	pears on the cover sheet with the	e correspondence address
• •		
A SHORTENED STATUTORY PERIOD FOR REPL WHICHEVER IS LONGER, FROM THE MAILING [ - Extensions of time may be available under the provisions of 37 CFR 1. after SIX (6) MONTHS from the mailing date of this communication If NO period for reply is specified above, the maximum statutory period Failure to reply within the set or extended period for reply will, by statu Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	DATE OF THIS COMMUNICATI .136(a). In no event, however, may a reply be d will apply and will expire SIX (6) MONTHS fr te, cause the application to become ABANDO	ON. be timely filed om the mailing date of this communication. NED (35 U.S.C. § 133).
Status		
1) Responsive to communication(s) filed on		
	 is action is non-final.	
3) Since this application is in condition for allowa		prosecution as to the merits is
closed in accordance with the practice under	•	
Disposition of Claims		
4)⊠ Claim(s) 1-11 is/are pending in the application	n.	
4a) Of the above claim(s) is/are withdra		
5) Claim(s) is/are allowed.		·
6) Claim(s) is/are rejected.		
7) Claim(s) is/are objected to.		
8) Claim(s) 1-11 are subject to restriction and/or	election requirement.	
Application Papers		
·· _	•	
9) The specification is objected to by the Examin		- Eversines
10) The drawing(s) filed on is/are: a) ac		
Applicant may not request that any objection to the		
Replacement drawing sheet(s) including the correct 11) The oath or declaration is objected to by the E		
•	.xammer. Note the attached Offi	de Action of form P 10-132.
Priority under 35 U.S.C. § 119		
12) Acknowledgment is made of a claim for foreig a) All b) Some * c) None of:	n priority under 35 U.S.C. § 119	(a)-(d) or (f).
1.☐ Certified copies of the priority documen	its have been received.	
2. Certified copies of the priority documen	•	ation No
3. Copies of the certified copies of the price		
application from the International Burea	au (PCT Rule 17.2(a)).	•
* See the attached detailed Office action for a lis	t of the certified copies not rece	ived.
•		
Attachment(s)		
1) Notice of References Cited (PTO-892)	4) Interview Summa	ary (PTO-413)
2) Notice of Draftsperson's Patent Drawing Review (PTO-948)	Paper No(s)/Mail	Date
3) Information Disclosure Statement(s) (PTO/SB/08)	5) Notice of Informa 6) Other:	al Patent Application
Paper No(s)/Mail Date	o, 🗀 Outer	

Application/Control Number: 10/664,008 Page 2

Art Unit: 1617

## **DETAILED ACTION**

## Election/Restrictions

- 1. Restriction to one of the following inventions is required under 35 U.S.C. 121:
  - I. Claims 1-11, drawn to a method of treating flaviviridae comprising administering a compound defined in claim 1, wherein X1, X2, Y and Z are oxygen, classified in class 514, subclass 450.
  - II. Claims 1-11, drawn to a method of treating flaviviridae comprising administering a compound defined in claim 1, wherein X1, X2, are oxygen, Y and Z are S, or N classified in class 514, subclass 213.01, 431.
  - III. Claims 1-7, 10-11, drawn to a method of treating flaviviridae comprising administering a compound defined in claim 1, wherein X1, X2, are -S-S-, -N-O-, -N-N-. Classified in class 514, subclass 213.01, 431.
  - IV. Claims 1-11, drawn to a method of treating flaviviridae comprising administering a compound defined in claim 1, wherein the compound containing Se, classified in class 514, subclass 185.
- 2. Inventions groups I-IV are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different designs, modes of operation, and effects (MPEP § 802.01 and § 806.06). In the instant case, the different inventions have different modes of operation. Particularly, the methods employ art recognized structurally distinct compounds. A reference rending obvious to one invention under 35 U.S.C. 103, would not necessarily rendering the other obvious as the compounds are not obvious each

Application/Control Number: 10/664,008

Page 3

Art Unit: 1617

from the others. Therefore, inventions of Group I-IV represent separate and distinct methods. Further, They therefore have different issues regarding patentability and enablement and represent patentable distinct subject matter.

- 3. Because these inventions are independent or distinct for the reasons given above and there would be a serious burden on the examiner if restriction is not required because the inventions have acquired a separate status in the art due to their recognized divergent subject matter, restriction for examination purposes as indicated is proper.
- 4. Claims 1-11 are generic to the following disclosed patentably distinct species: various viral infections. The species are independent or distinct because of distinct etiologies. Applicant is required under 35 U.S.C. 121 to elect a single disclosed species, even though this requirement is traversed. Applicant is advised that a reply to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which depend from or otherwise require all the limitations of an allowable generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

Art Unit: 1617

Applicant is advised that the reply to this requirement to be complete must include (i) an election of a species or invention to be examined even though the requirement be traversed (37 CFR 1.143) and (ii) identification of the claims encompassing the elected invention.

The election of an invention or species may be made with or without traverse. To reserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the restriction requirement, the election shall be treated as an election without traverse.

Should applicant traverse on the ground that the inventions or species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the inventions or species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C.103(a) of the other invention.

5. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Shengjun Wang whose telephone number is (571) 272-0632. The examiner can normally be reached on Monday to Friday from 7:00 am to 3:30 pm.

Application/Control Number: 10/664,008 Page 5

Art Unit: 1617

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Sreeni Padmanabhan, can be reached on (571) 272-0629. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

FRIMARY EXAMIN Shengjun Wang Primary Examiner Art Unit 1617